Tailoring Endocrine Therapy in Breast Cancer Patients
Tailoring Endocrine Therapy in Breast Cancer Patients
Nearly 215,000 cases of invasive breast cancer are diagnosed in the United States each year, approximately three-quarters of which are estrogen receptor (ER) or progesterone receptor-positive. Our knowledge of the benefits of interfering with the ER-signaling pathway and treatment options for those with hormone receptor-positive disease have improved substantially with the development of aromatase inhibitors (AIs). For younger premenopausal women, the optimal use of tamoxifen with ovarian suppression/ovarian ablation (OS/OA) remains unresolved. Cianfrocca and Wolff provide a comprehensive and thoughtful review of these issues, highlighting current and ongoing studies of endocrine therapies in the adjuvant setting for both patient populations.
Aromatase Inhibitors, Tamoxifen, or Both?
A large collective body of information has shown that (1) ER signaling is important in breast cancer growth and spread, (2) hormone receptor status is a strong predictor for endocrine therapy effectiveness, (3) endocrine therapy is only effective in those who are hormone receptor-positive (although a subset of these patients may exhibit de novo or acquired resistance), and (4) endocrine therapy can dramatically decrease breast cancer recurrence and death. While 5 years of adjuvant tamoxifen has been considered the treatment standard based on individual studies and the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview analyses, recent studies suggest a superior disease-free survival with AI therapy.
The first and largest of these studies, the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, was a direct comparison of anastrozole (Arimidex) and tamoxifen and currently has over 5 years of follow-up. The Breast International Group (BIG) 1-98 trial shows similar results with letrozole (Femara), although this trial is less mature.[4,5] Alternatively, the sequential treatment strategies of 2, 3, or 5 years of tamoxifen followed by an AI have all shown a disease-free survival benefit compared with 5 years of tamoxifen.[6,7] One of these studies (the Arimidex-Nolvadex [ARNO] trial) has shown a survival benefit at 30.1 months.
Thus, there is little controversy that postmenopausal women with hormone receptor-positive breast cancer should receive an aromatase inhibitor as part of their adjuvant therapy. What remains unclear is the optimal sequence of these therapies. Preclinical data suggest that tamoxifen may be more beneficial used early in the sequence of antiestrogen therapy, as xenografts selected for resistance to tamoxifen will respond to an aromatase inhibitor but AI-resistant tumors do not respond to tamoxifen.[9,10] However, direct comparisons of AI therapy upfront vs following tamoxifen have not yet matured and await results from BIG 1-98.
Proponents of upfront aromatase inhibitors argue that patients should not be denied the small but significant benefit of an AI early in the course of therapy for this theoretical advantage of starting with tamoxifen. In addition, because all crossover studies reported to date randomized patients after an initial treatment period with tamoxifen, those patients who may have had more aggressive disease and had early recurrences would have already been excluded. It is certainly reasonable to begin with an aromatase inhibitor for postmenopausal hormone-sensitive breast cancer, particularly when the patient is at higher risk for early recurrence. For each patient, careful consideration should be given to the differing short- and long-term toxicities of these two classes of agents. In the future, it is likely that tumor and host profiling studies will help guide treatment on a more individual basis.
A number of critical questions remain. What do we recommend to women who have completed 5 years of an AI or a combination of tamoxifen and an AI for 5 years? If additional therapy is chosen, what should it be? Are there significant differences among the third-generation AIs? It seems likely that 3 years of an AI, even when preceded by tamoxifen, may not be adequate therapy for those with higher-risk disease. Current studies do not address these questions, and rerandomization beyond 5 years of hormonal therapy is again necessary, as extrapolation from 10-year tamoxifen data may not be applicable. In addition, the ongoing MA.27 trial should provide direct comparative data for 5 years of adjuvant anastrozole vs exemestane (Aromasin) therapy.
Endocrine Therapy in Premenopausal Women
For younger women with hormone receptor-positive breast cancer, endocrine therapy is clearly effective, and understanding the optimal treatment regimen is critical. There are no prospective, randomized trials that address the role of ovarian ablation in the context of current treatment regimens. Older studies show convincingly that OA/OS is equivalent to CMF-based chemotherapy (cyclophosphamide, methotrexate, fluorouracil) and offers benefit similar to that of tamoxifen in premenopausal patients with hormone receptor-positive disease. However, common practice in North America is to offer these patients chemotherapy followed by tamoxifen, and the additional benefit of OA/OS in this situation is unclear. Furthermore, the benefit of OA/OS compared with anthracycline- and taxane-based chemotherapy has not been explored.